IOL Chemicals & Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹580Cr
- +10.9% YoY
- +2.1% QoQ
- Net profit
- ₹21Cr
- 0% YoY
- −30% QoQ
- Margin
- 10%
- +1 pp YoY
- 0 pp QoQ
Guidance rank: #30 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
The company expects a minimum 10% to 15% growth in top line (sales/revenue) in the coming year (FY '27). Company expects 10% to 15% growth in top line for FY '27.
From IOL Chemicals & Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company expects a minimum 10% to 15% growth in top line (sales/revenue) in the coming year (FY '27).
- Bottom-line growth is anticipated between 15% to 20%.
- The focus is on increasing exports, especially of pharmaceutical products, including efforts to boost the non-ibuprofen (non-ibu) API share.
- Capacity utilization is high for pharma (above 90%), except paracetamol which is expanding; chemicals utilization is near 200%.
- The paracetamol segment is expected to be a key growth driver, alongside metformin and the shift of non-ibu domestic sales to regulated markets.
- New capacities are being planned, with ongoing capex of around INR 150-200 crores annually.
2 more points from IOL Chemicals & Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what IOL Chemicals & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY '26 capex budget was around INR 150 crores; actual expected slightly lower (~INR 130-135 crores).
- Approximately 60% of FY '26 capex directed towards growth, and 40% towards infrastructure development and automation.
- For FY '27, the company plans a similar level of capex (~INR 150-200 crores), though final plans are yet to be finalized.
- Capex aims to support increased capacity, particularly expanding key products like paracetamol and non-ibuprofen APIs.
2 more points from IOL Chemicals & Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what IOL Chemicals & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from IOL Chemicals & Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
IOL Chemicals & Pharmaceuticals Ltd — Quarterly revenue & net profit
IOL Chemicals & Pharmaceuticals Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 580 | 523 | +10.9% | 568 | +2.1% |
| Operating profit (EBITDA) | 57 | 47 | +21.3% | 57 | 0% |
| Operating margin | 10% | 9% | +1 pp | 10% | 0 pp |
| Profit before tax | 28 | 28 | 0% | 41 | -31.7% |
| Net profit (PAT) | 21 | 21 | 0% | 30 | -30% |
| EPS (₹) | 0.70 | 0.70 | 0% | 1.02 | -31.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹795 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What IOL Chemicals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
IOL Chemicals & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were IOL Chemicals & Pharmaceuticals Ltd Q3 FY26 results?
The company expects a minimum 10% to 15% growth in top line (sales/revenue) in the coming year (FY '27). Company expects 10% to 15% growth in top line for FY '27.
What is IOL Chemicals & Pharmaceuticals Ltd share price analysis?
IOL Chemicals & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 32.8 with a market cap of ₹4,797 Cr. Investors should review the full earnings analysis for detailed insights.
Is IOL Chemicals & Pharmaceuticals Ltd planning capital expenditure?
FY '26 capex budget was around INR 150 crores; actual expected slightly lower (~INR 130-135 crores).
Keep IOL Chemicals & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
